Slide 1: Half Year Financial Results and Business Update
For personal use only Half Year Financial Results and Business Update 19 February 2014
Slide 2: Introduction
Introduction For personal use only • Cogstate is a medical technology company with products to test cognitive decline and train the brain to improve performance. • First-to-market with COGNIGRAM – patient point of care cognitive testing technology with Merck Canada. • Early detection tools for Alzhe
Slide 3: Leading the Field
Leading the Field For personal use only Clinical Trials Axon Sports Cogstate Research COGNIGRAM™ Playing an integral role Cutting edge tools to Accepted and used Giving GPs tools for in cognition-related assess, monitor and globally in critical accurate, easy clinical trials improve the athletic stu
Slide 4: Summary of Results
Summary of Results For personal use only • Total revenue recognised A$5.43 million. • Positive outlook : US$18m of Clinical Trial Revenue to be recognised in future periods at 31 January 2014, compared to US$11.38 million in December 2012. • Record value of clinical trial contracts awarded during De
Slide 5: H1FY2014: Recognised Revenue
H1FY2014: Recognised Revenue For personal use only Revenue Breakdown - A$ Growth 31 December 2013 31 December 2012 Clinical Trials Segment (16.8%) 4,828,429 5,804,063 Sports Segment 84.4% 500,967 271,734 Healthcare Segment - 10,127 - Other - 40,732 - Revenue from Customers (11.4%) 5,380,255 6,075,79
Slide 6: New Contracts Won in Clinical Trials
New Contracts Won in Clinical Trials For personal use only • New contracts for computerised tests as well as Cogstate’s rater Cogstate Clinical Trials training services. Committed Future Revenue 20,000,000 • New paediatric studies further 18,000,000 16,000,000 validating Cogstate’s utility in that 1
Slide 7: Clinical Trials: Growing validation beyond Alzheimers
Clinical Trials Growing validation beyond Alzheimers For personal use only • Cogstate has great acceptance and published validation as being sensitive to amyloid related cognitive deterioration. • Increased contracted sales (booking): • Work underway to increase the software component of sales (bett
Slide 8: COGNIGRAM: The Cogstate Test
COGNIGRAM The Cogstate Test For personal use only
Slide 9: COGNIGRAM: A unique and valued product for GPs
COGNIGRAM A unique and valued products for GPs For personal use only • COGNIGRAM a unique product to assist GPs in the diagnosis of dementia – an easy to use and accurate in-clinic tool. • Usability and utility data from Canada will inform product launch in other territories: • Significant learnings
Slide 10: COGNIGRAM: Sensitivity & specificity of memory composite
COGNIGRAM Sensitivity & specificity of memory composite For personal use only MCI AD Sensitivity Sensitivity = 81% Sensitivity = 100% Specificity = 82% Specificity = 92% 100 - Specificity 100 - Specificity Maruff et al. Accepted Alzheimer’s Association Meeting (AAIC) Boston 2013
Slide 11: Axon Sports
Axon Sports For personal use only • Provide college and professional athletes advanced cognitive training tools and technology as part of a program for cognitive skill development. • High-definition touch screen monitors combined with lighting and sound create an ideal cognitive training environment
Slide 12: Cogstate Research
Cogstate Research For personal use only • Cogstate developed a global reputation for engaging in world class research; – Psychological and neuropsychological – Genetic and medical conditions • Wealth of research studies involving Cogstate and the important role that research plays across the busines
Slide 13: New growth opportunities: Monetizing Big Data
New growth opportunities Monetizing Big Data For personal use only • Cogstate has collected a unique dataset of cognitive indicators that can be used to better understand the risk of activities involving cognition within demographic and geographic populations. • 150,000 individual records, across ag
Slide 14: New phase in the evolution of Cogstate
New phase in the evolution of Cogstate For personal use only • Four business lines established, significant investment into new commercial opportunities underway • New revenue streams in FY13 marks the beginning of Cogstate has an new and significant commercial opportunities: exceptional opportunity
Slide 15: For personal use only
For personal use only COGSTA’lhe ASSESS + MONITOR « IMPROVE